Literature DB >> 10634364

Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men.

S Grinspoon1, C Corcoran, T Stanley, A Baaj, N Basgoz, A Klibanski.   

Abstract

Hypogonadism is prevalent among human immunodeficiency virus-infected men, in whom significantly reduced quality of life and mood disturbances have been reported. Previous studies have not investigated the relationship between depression score and gonadal function among such patients. We first compared depression scores in hypogonadal (n = 52) and eugonadal (n = 10) patients with acquired immunodeficiency syndrome (AIDS) wasting, matched for weight and disease status, and then investigated the effects of testosterone administration on depression score in a randomized, double-blind, placebo-controlled study among the group of hypogonadal men with AIDS wasting. The primary end point in all comparisons was the Beck Depression Inventory. Hypogonadal patients demonstrated significantly increased scores on the Beck inventory compared with eugonadal-, age-, weight-, and disease status-matched subjects (15.5+/-1.1 vs. 10.6+/-1.4 mean +/- SEM, P = 0.02). Among the combined hypogonadal and eugonadal subjects, a significant inverse correlation was seen between the Beck score and both free (r = 0.41, P<0.01) and total serum testosterone levels (r = -0.43, P<0.001). The relationship between the Beck score and testosterone levels remained highly significant, controlling for weight, viral load, CD4 count, and antidepressant use (P<0.01 for free testosterone, P<0.001 for total testosterone). Furthermore, when subjects were divided into two groups, based on a Beck score greater than 18 or less than or equal to 18, serum total and free testosterone levels were significantly lower in the subjects with a Beck score greater than 18, whereas there were no differences in weight, viral load, CD4 count, or Karnofsky status. End of study data were available in 39 patients who completed the randomized, placebo-controlled study. Beck score decreased significantly only in the subjects receiving testosterone (-5.8+/-1.3, P< 0.001), but not in subjects randomized to placebo (-2.7+/-1.3, P> 0.05). In a regression analysis, the change in Beck score was related significantly to change in weight (P<0.01). These data demonstrate increased depression score in association with hypogonadism in men with AIDS wasting, independent of weight, virologic status, and other disease factors. In such patients, administration of testosterone results in a significant improvement in depression inventory score. This effect may be a direct effect of testosterone or related to positive effects of testosterone on weight and/or other anthropometric indices. Additional studies are needed to assess the effects of testosterone on clinical depression indices in human immunodeficiency virus-infected patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10634364     DOI: 10.1210/jcem.85.1.6224

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  26 in total

Review 1.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

2.  Sarcopenia during androgen-deprivation therapy for prostate cancer.

Authors:  Matthew R Smith; Fred Saad; Blair Egerdie; Paul R Sieber; Teuvo L J Tammela; Chunlei Ke; Benjamin Z Leder; Carsten Goessl
Journal:  J Clin Oncol       Date:  2012-05-29       Impact factor: 44.544

Review 3.  Androgens and male aging: Current evidence of safety and efficacy.

Authors:  Louis J Gooren
Journal:  Asian J Androl       Date:  2010-02-15       Impact factor: 3.285

Review 4.  Hypogonadism in human immunodeficiency virus-positive men.

Authors:  Jane Ashby; David Goldmeier; Hossein Sadeghi-Nejad
Journal:  Korean J Urol       Date:  2014-01-15

Review 5.  A practical guide to male hypogonadism in the primary care setting.

Authors:  P Dandona; M T Rosenberg
Journal:  Int J Clin Pract       Date:  2010-05       Impact factor: 2.503

Review 6.  Metabolic complications of androgen deprivation therapy for prostate cancer.

Authors:  Philip J Saylor; Matthew R Smith
Journal:  J Urol       Date:  2009-03-14       Impact factor: 7.450

7.  Pharmacologically induced hypogonadism and sexual function in healthy young women and men.

Authors:  Peter J Schmidt; Emma M Steinberg; Paula Palladino Negro; Nazli Haq; Carolyn Gibson; David R Rubinow
Journal:  Neuropsychopharmacology       Date:  2008-03-19       Impact factor: 7.853

Review 8.  Illicit anabolic-androgenic steroid use.

Authors:  Gen Kanayama; James I Hudson; Harrison G Pope
Journal:  Horm Behav       Date:  2009-09-18       Impact factor: 3.587

Review 9.  The many faces of testosterone.

Authors:  Jerald Bain
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

10.  The benefits and risks of testosterone replacement therapy: a review.

Authors:  Nazem Bassil; Saad Alkaade; John E Morley
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.